SCHEMBL495622

SCHEMBL495622

O=C(O)c1cc(Cl)ccc1NC1CCCCC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 4/20 0.57
CISD1 Q9NZ45 1/20 0.56
CA12 O43570 1/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
CA3 P07451 1/20 0.56
CA4 P22748 1/20 0.56
CA6 P23280 1/20 0.56
CA7 P43166 1/20 0.56
CA9 Q16790 1/20 0.56
CA13 Q8N1Q1 1/20 0.56
CA14 Q9ULX7 1/20 0.56
CA5B Q9Y2D0 1/20 0.56
GRIK1 P39086 1/20 0.55
GRIA2 P42262 1/20 0.55
KDM4E B2RXH2 2/20 0.53
HSD17B10 Q99714 2/20 0.53
ALDH1A1 P00352 2/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1397540 0.92 GRIK1 (0.62) SERPINE1CISD1CA12CA1CA2
SCHEMBL19915082 0.87 RAB9A (0.53) SERPINE1CA1CA2CA3CA6
SCHEMBL495805 0.86 TSHR (0.54) SERPINE1CISD1CA12CA1CA2
SCHEMBL11637463 0.85 MAPT (0.55) SERPINE1KDM4EALDH1A1MEN1KMT2A
SCHEMBL495339 0.84 YAP1 (0.65) KDM4EALDH1A1MEN1KMT2ARAB9A
SCHEMBL13280193 0.79 MEN1 (0.51) SERPINE1CISD1CA12CA1CA2
SCHEMBL3786467 0.79 KMT5B (0.54) KDM4EALDH1A1MEN1KMT2ARAB9A
SCHEMBL11168379 0.78 KDM4E (0.59) SERPINE1KDM4EHSD17B10ACLY
SCHEMBL5113833 0.78 LIPC (0.60) CISD1CA12CA1CA2CA3
SCHEMBL3477479 0.78 RAB9A (0.58) KDM4EALDH1A1MEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1955697-B1 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER ASTELLAS PHARMA INC (JP) 2012-05-02 EP disclosed
US-8106190-B2 2-aminobenzamide derivatives ASTELLAS PHARMA INC. (JP) 2012-01-31 US disclosed
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-09-17 US disclosed
CN-101312720-A 2-aminobenzamide derivative ASTELLAS PHARMA INC (JP) 2008-11-26 CN disclosed
EP-1955697-A1 2-AMINOBENZAMIDE DERIVATIVE Astellas Pharma Inc. (JP) 2008-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE TRPV1, TRPV2, TRPV5 SERPINE1 2154/4885CISD1 1671/4885CA12 3007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.